Analyst firms · Piper Sandler · SLDB
Piper Sandler SLDB price target and rating history
Solid Biosciences Inc. (SLDB) · Health Care
Piper Sandler rates Solid Biosciences Inc. (SLDB) Overweight with a $20 price target, as of its latest action on May 31, 2024. It has published 3 rating actions on SLDB since July 2021, including 1 upgrade and 0 downgrades. Across 5 firms with a SLDB price target in the last 12 months, the median target is $20.
- Current rating
- Overweight
- Price target
- $20
- Median target, all firms
- $20
- Actions on SLDB
- 3
Piper Sandler price target on SLDB
Every Piper Sandler rating on SLDB
- May 31, 2024
- Mar 14, 2024
- Jul 12, 2021
How other firms rate SLDB
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| William Blair | Outperform | Nov 9, 2026 | |
| UBS | Buy | $20 | Oct 15, 2026 |
| RBC Capital Markets | Outperform | $18 | Sep 16, 2026 |
| Truist Securities | Buy | $20 | Aug 21, 2026 |
| Guggenheim | Buy | $26 | Mar 20, 2026 |
| Needham | Buy | $16 | Dec 4, 2025 |
Questions about Piper Sandler and SLDB
- What is Piper Sandler's price target for SLDB?
- Piper Sandler's latest stated price target for Solid Biosciences Inc. (SLDB) is $20, from its action on May 31, 2024.
- What is Piper Sandler's rating on SLDB?
- Piper Sandler rates SLDB Overweight, a bullish rating, as of May 31, 2024.
- When did Piper Sandler last change its view on SLDB?
- On May 31, 2024, Piper Sandler resumes coverage at Overweight, price target $20.
- How does Piper Sandler's SLDB target compare with other analysts?
- Across 5 firms with a SLDB price target in the last 12 months, the median target is $20.
All Piper Sandler ratingsSLDB news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.